UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

A UCLA study found that traditional pathological features do not predict who will benefit more from adding hormone therapy to postoperative radiation. 

Jordyn Silverstein, MD, MSc, discusses updated data with abemaciclib plus hormonal therapy in ER-positive endometrial cancer and low-grade serous ovarian cancer.

Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in ovarian and endometrial cancer.

Top experts discuss the most important takeaways and data to come out of this year’s ASCO Annual Meeting in non–small cell lung cancer.

Experts go step by step in laying out their thought processes and treatment selections for difficult-to-treat lung cancer cases.

Edward B. Garon, MD, MS, details how frontline therapy shapes sequencing in relapsed/refractory EGFR-mutated non–small cell lung cancer.

Jay M. Lee, MD, discusses the role of ctDNA in guiding surveillance and treatment escalation decisions in resected NSCLC.

Amy L. Cummings, MD, discusses patient selection for adjuvant immunotherapy in resectable non–small cell lung cancer.

Gerald Soff, MD, discusses the phase 3 RECITE trial, which evaluated romiplostim for the treatment of persistent chemotherapy-induced thrombocytopenia in patients with GI cancer.

Zev A. Wainberg, MD, discusses the rapidly evolving landscape of KRAS-directed therapy in PDAC from pan-RAS inhibition to KRAS G12D–specific strategies.

Read a refresh of the top FDA news in breast cancer from May 2026, including several key approvals across ER-positive and triple-negative disease.

The FDA extended the review period for camizestrant plus a CDK4/6 inhibitor in hormone receptor–positive breast cancer with an emergent ESR1 mutation.

Rena D. Callahan, MD, discusses the clinical implications of the FDA approval of Dato-DXd for the treatment of patients with unresectable/metastatic TNBC.

Alexis Ann LeVee, MD, highlights breast cancer abstracts to pay attention to at the 2026 ASCO Annual Meeting.

Danvatirsen in combination with pembrolizumab did not result in an ORR improvement vs pembrolizumab alone in first-line recurrent/metastatic HNSCC.

Experts spotlight the triple-negative breast cancer abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Breast cancer experts spotlight the abstracts they’re most excited to see at the 2026 ASCO Annual Meeting.

Rena D. Callahan, MD, discusses the clinical utility and shifting paradigms of oral SERDs for patients with ER-positive advanced breast cancer.

Rena D. Callahan, MD, discusses questions regarding treatment sequencing with CDK4/6 inhibitors and ADCs in hormone receptor–positive breast cancer.

Rena D. Callahan, MD, notes the implications of adding camizestrant to an aromatase inhibitor in ER-positive breast cancer with an emergent ESR1 mutation.

Rena D. Callahan, MD, discusses the implications of the NATALEE trial of adjuvant ribociclib plus endocrine therapy in HR-positive early breast cancer.

A new UCLA study suggests the organization of immune cells inside melanoma tumors may help show which patients benefit from combination immunotherapy

Low-cost blood tests that detect multiple blood cancers and diseases have been developed by researchers at UCLA Health.

Marla D. Lipsyc-Sharf, MD, highlights the clinical evolution of the Signatera Genome test for residual disease surveillance in patients with breast cancer.

Marla D. Lipsyc-Sharf, MD, discusses the evolving role of MRD ctDNA testing in breast cancer management and aiding in early detection of disease recurrence.

Dr Bardia discusses key findings from the phase 3 lidERA Breast Cancer study of giredestrant in estrogen receptor–positive, HER2-negative breast cancer.

Aditya Bardia, MD, MPH, FASCO, discusses the design of the ELEGANT study of elacestrant vs endocrine therapy in high-risk, ER-positive early breast cancer.

Deborah J. Wong, MD, PhD, discusses data with ficerafusp alfa plus pembrolizumab in HPV-negative HNSCC.

The top 5 OncLive TV videos of the week cover insights in multiple myeloma, myelodysplastic syndrome, breast cancer, colorectal cancer, and cervical cancer.

Dr Bardia discusses the ELEGANT study of elacestrant in estrogen receptor–positive, HER2-negative early breast cancer at high risk of disease recurrence.